Both thapsigargin- and tunicamycin-induced endoplasmic reticulum stress increases expression of Hrd1 in IRE1-dependent fashion.


Journal

Neurological research
ISSN: 1743-1328
Titre abrégé: Neurol Res
Pays: England
ID NLM: 7905298

Informations de publication

Date de publication:
Feb 2019
Historique:
pubmed: 27 11 2018
medline: 5 3 2019
entrez: 27 11 2018
Statut: ppublish

Résumé

We have investigated the impact of endoplasmic reticulum (ER) stress, which is often implicated in neurodegenerative diseases, on the expression of Hrd1, an E3 ubiquitin ligase that plays a central role in the process of ER-associated degradation (ERAD). SH-SY5Y neuroblastoma cells, a frequently used model for studying neurotoxicity in dopaminergic neurons and the mechanisms of neurodegeneration associated with Parkinson's disease, and parental SK-N-SH cells were studied. We demonstrate that ER stress, induced by thapsigargin or tunicamycin, correlates with the increased expression of Hrd1 in both SH-SY5Y and SK-N-SH cells. Inhibition of PERK does not significantly suppress the thapsigargin- or tunicamycin-induced expression of Hrd1. Nevertheless, PERK inhibition has a positive effect on the survival of SH-SY5Y cells treated with thapsigargin but not on those treated with tunicamycin. Inhibition of IRE1 associated with the inhibition of XBP1 splicing does not affect the survival of SH-SY5Y cells treated with either thapsigargin or tunicamycin but results in the complete suppression of both the thapsigargin- and tunicamycin-induced expression of Hrd1. Thus, the ER-stress-induced expression of Hrd1 in SH-SY5Y depends on Hrd1 transcription activation, which is a consequence of IRE1 but not of PERK activation.

Identifiants

pubmed: 30475171
doi: 10.1080/01616412.2018.1547856
doi:

Substances chimiques

Anti-Infective Agents 0
Enzyme Inhibitors 0
Tunicamycin 11089-65-9
Thapsigargin 67526-95-8
SYVN1 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
ERN1 protein, human EC 2.7.11.1
PERK kinase EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
eIF-2 Kinase EC 2.7.11.1
Endoribonucleases EC 3.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

177-188

Auteurs

Katarina Dibdiakova (K)

a Jessenius Faculty of Medicine in Martin (JFM CU), Biomedical Center Martin JFM CU and Department of Medical Biochemistry JFM CU , Comenius University in Bratislava , Martin , Slovakia.

Simona Saksonova (S)

a Jessenius Faculty of Medicine in Martin (JFM CU), Biomedical Center Martin JFM CU and Department of Medical Biochemistry JFM CU , Comenius University in Bratislava , Martin , Slovakia.

Ivana Pilchova (I)

a Jessenius Faculty of Medicine in Martin (JFM CU), Biomedical Center Martin JFM CU and Department of Medical Biochemistry JFM CU , Comenius University in Bratislava , Martin , Slovakia.

Katarina Klacanova (K)

a Jessenius Faculty of Medicine in Martin (JFM CU), Biomedical Center Martin JFM CU and Department of Medical Biochemistry JFM CU , Comenius University in Bratislava , Martin , Slovakia.

Zuzana Tatarkova (Z)

a Jessenius Faculty of Medicine in Martin (JFM CU), Biomedical Center Martin JFM CU and Department of Medical Biochemistry JFM CU , Comenius University in Bratislava , Martin , Slovakia.

Peter Racay (P)

a Jessenius Faculty of Medicine in Martin (JFM CU), Biomedical Center Martin JFM CU and Department of Medical Biochemistry JFM CU , Comenius University in Bratislava , Martin , Slovakia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH